ASH 2024: Research Highlights in CLL/SLL

Out of the many research publications being presented at the ASH 2024 conference for chronic lymphocytic leukemia (CLL), read about some of the session topics from today. Stay tuned for coverage of these topics at HealthTree Conference Coverage in the coming weeks. 

Discussing New Treatments for Relapsed/Refractory CLL and Quality of Life 

In an afternoon session titled “Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life,” some of the topics for relapsed/refractory CLL included: 

• How effective is the bispecific antibody epcoritamab (Epkinly by Genmab and AbbVie) when used by itself?
• Reviewing early data on the effectiveness and safety of BTK degraders NX-5948 (by Nurix Therapeutics) and BGB-16673 (by BeiGene).
• The effects of combining CAR T-cell therapy liso-cel (Breyanzi by BMS) with ibrutinib (Imbruvica, by Johnson & Johnson).
• Follow-up data about the non-covalent BTK inhibitor pirtobrutinib (Jaypirca by Eli Lilly).
• MRD-guided treatment with ibrutinib and venetoclax (Venclexta, by AbbVie) improves patient quality of life. 

Treatment Combinations for First-Time Treated CLL 

In an evening session titled “Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations,” some of the topics for first-time treated CLL included: 

• Information about a fixed-duration treatment combination of acalabrutinib (Calquence, AstraZeneca) and venetoclax, with or without obinutuzumab (Gazyva, by Genentech).
• Changing how long you receive venetoclax and obinutuzumab based on your MRD test results.
• Combining pirtobrutinib, venetoclax, and obinutuzumab.
• Data about the treatment combination of sonrotoclax (by BeiGene) and zanubrutinib (Brukinsa by BeiGene).
• Testing MRD after the combination of ibrutinib and venetoclax followed by ibrutinib and obinutuzumab.
• Reviewing results of the treatment combination atezolizumab (Tecentriq by Genentech), venetoclax, and obinutuzumab. 

Additional Popular Topics 

Other highlights from ASH 2024 for CLL to watch news coverage for include: 

• Factors that influence patients taking CLL treatments like finances and health-related quality of life 
• Long-term data on how CAR T-cell therapy affects people with CLL
• Ibrutinib’s impact on CLL patients who are in the early stages of the cancer with no symptoms
• Factors that influence CLL/SLL patients' decisions for choosing a BTK inhibitor  

Stay Tuned! 

We’re excited to cover this important information on your behalf in the upcoming weeks, writing in a way that is easy to understand. Bookmark the link below to view the news about published conference coverage. 

HealthTree Conference Coverage

Sources: 

• Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life
• Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations
• Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy
• Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
• Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)
• Financial Toxicity, Health-Related Quality of Life, and Medication Adherence Patient-Reported Outcomes (PROs) in Patients with Chronic Lymphocytic Leukemia (CLL) on First-Line Oral Oncolytics